Physician profile
Amelia Prado
NPI 1598830069
$4,002.85
in general payments reported to CMS, 2019-2025
30 companies · $751 in 2025
The $751 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $736 · 2020: $216 · 2021: $1,165 · 2022: $528 · 2023: $478 · 2024: $128 · 2025: $751.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,357.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,357.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $708.71 | 2019-2025 | Ozempic, Wegovy |
| Amgen INC. | $561.72 | 2019-2025 | Repatha |
| Biohaven Pharmaceuticals, INC. | $463.20 | 2021 | |
| Allergan, INC. | $364.31 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $224.62 | 2023-2025 | Tezspire, Fasenra |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $224.32 | 2023 | |
| Heartflow, INC. | $167.30 | 2025 | |
| W. L. Gore & Associates, INC. | $148.48 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $136.74 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $128.33 | 2019 | |
| Abbvie INC. | $117.39 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $116.75 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $104.74 | 2023 | Livalo, Seglentis |
| Nevro Corp. | $97.82 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $74.51 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $57.21 | 2022-2023 | Aptima, Thinprep 2000 Processor |
| Paratek Pharmaceuticals, INC. | $40.27 | 2021 | |
| Alexion Pharmaceuticals, INC. | $36.00 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.39 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $30.24 | 2021 | |
| Scilex Pharmaceuticals INC. | $26.68 | 2021 | |
| Neurocrine Biosciences, INC. | $18.42 | 2021 | |
| Gilead Sciences, INC. | $18.39 | 2019 | |
| Medtronic, INC. | $16.66 | 2022 | |
| Pfizer INC. | $16.22 | 2021 | |
| Daiichi Sankyo INC. | $16.15 | 2021 | |
| Boston Scientific Corporation | $15.11 | 2022 | |
| Sunovion Pharmaceuticals INC. | $14.05 | 2021 | |
| Glaxosmithkline, LLC. | $13.82 | 2019 | |
| Nestle Healthcare Nutrition INC. | $13.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amelia Prado listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.